Quigley Jill M. 4
4 · Terns Pharmaceuticals, Inc. · Filed Jul 17, 2024
Insider Transaction Report
Form 4
Quigley Jill M.
Director
Transactions
- Exercise/Conversion
Common Stock
2024-07-15$1.82/sh+14,365$26,144→ 44,365 total - Sale
Common Stock
2024-07-15$10.00/sh−14,365$143,660→ 30,000 total - Exercise/Conversion
Common Stock
2024-07-16$1.82/sh+400$728→ 30,400 total - Sale
Common Stock
2024-07-16$10.00/sh−400$4,000→ 30,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-15−14,365→ 17,635 totalExercise: $1.82From: 2023-06-12Exp: 2032-06-15→ Common Stock (14,365 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-07-16−400→ 17,235 totalExercise: $1.82From: 2023-06-12Exp: 2032-06-15→ Common Stock (400 underlying)
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
- [F2]This sale price represents the weighted average sale price of the shares sold ranging from $10.00 to $10.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The option vested in full immediately prior to the Annual Meeting following the date of grant.